Brief: Fusen Pharma Updates Regarding A Licence Agreement
10/02/2021 15:04
Feb 10 (Reuters) - Fusen Pharmaceutical Company Ltd
1652.HK :
* JIANGXI YONGFENG KANGDE PHARMA AND BIKA BIOTECHNOLOGY
(GUANGZHOU) CO ENTERED INTO LICENCE AGREEMENT
* JIANGXI KANGDE, BIKA TO COLLABORATE IN RESEARCH AND
DEVELOPMENT,
COMMERCIALISATION OF PRODUCTS RELATED TO DOCETAXEL INJECTION
Source text for Eikon: ID:nHKSbNxPz0
Further company coverage: 1652.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fusen Pharmaceutical
See all newsBrief: Fusen Pharmaceutical Logs HY Loss Attributable RMB13.6 Million
Brief: Fusen Pharmaceutical Says Doxazosin Mesylate Extended-Release Tablets Approved For Marketing In China
Brief: Fusen Pharmaceutical Says Peramivir Injection First Neuraminidase Inhibitor Approved In China For Intravenous Influenza Treatment
Brief: Fusen Pharmaceutical Says Investors To Contribute RMB300 Mln For 34% Stake Subscription Of Henan Fusen Pharmaceutical
Brief: Fusen Pharmaceutical Says Piracetam Injection Approved For Marketing By NMPA